Jul
22 2010

Aquapharm and AMRI Enter Into a Novel Marine Chemistry Collaboration

Aquapharm Biodiscovery, a leading marine biotechnology company, has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.

Under the terms of this agreement, drawing on its substantial experience and expertise from previous screening campaigns with its terrestrial natural products library, AMRI will screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target and will isolate and elucidate the structures of novel hits. Aquapharm retains all rights to compounds resulting from the collaboration.

More info

From Issue 11 • Categories: Tags: , , , , , • No Comments
Dec
16 2009

Aquapharm adds to team to facilitate commercialization of marine biotech products

Aquapharm has made two major appointments to help it move closer to commercializing its marine biotech assets.

Jon Williams joins Aquapharm as business development director with a remit to explore non-pharmaceutical markets for its products in areas such as personal care, food, nutrition and industrial chemistry.

Also signing up at the Oban-based firm is Dr Lloyd Payne who becomes research director.

Payne is being charged with delivering the completion of the world’s largest marine-derived compound library which the company hopes to unveil to the market next year.

Andrew Spragg, chief executive and founder of Aquapharm, said: “Because we have this growing portfolio, we need people with specific sector experience.

“Jon’s considerable experience in the commercialisation of natural products will be invaluable.This appointment will catalyse our efforts to establish sustainable, diversified sources of revenue and act to support the longer-term development of novel pharmaceutical candidates.

More info

From Issue 8 • Categories: Tags: , • No Comments
May
11 2009

Aquapharm and Dr. Reddy’s Sign Commercial License Agreements

Scottish marine biotechnology company Aquapharm Biodiscovery Limited signed a new commercial license agreement and an extended an existing research and development license agreement with Dr. Reddy’s Laboratories Limited. The commercial license covers selected strains from the Aquapharm library of novel marine microorganisms. These strains will be used to generate commercial biocatalysts for specific applications in the manufacture of pharmaceutical intermediates at the Dr. Reddy’s R&D site at Cambridge, UK. Under these agreements, Aquapharm will receive milestone payments as well as royalties on commercialization of the product by Dr. Reddy’s.

More Info

From Issue 3 • Categories: Tags: , , , , , • No Comments